C. Harvengt

1.2k total citations
100 papers, 1.0k citations indexed

About

C. Harvengt is a scholar working on Pharmacology, Endocrinology, Diabetes and Metabolism and Surgery. According to data from OpenAlex, C. Harvengt has authored 100 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Pharmacology, 22 papers in Endocrinology, Diabetes and Metabolism and 20 papers in Surgery. Recurrent topics in C. Harvengt's work include Antibiotics Pharmacokinetics and Efficacy (14 papers), Lipoproteins and Cardiovascular Health (12 papers) and Pharmacology and Obesity Treatment (9 papers). C. Harvengt is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (14 papers), Lipoproteins and Cardiovascular Health (12 papers) and Pharmacology and Obesity Treatment (9 papers). C. Harvengt collaborates with scholars based in Belgium, Luxembourg and Germany. C. Harvengt's co-authors include J.P. Desager, F. Heller, Yves Horsmans, Jean‐Pierre Desager, R. Hulhoven, Catherine Vandenplas, P. De Schepper, Yves Horsmans, F. Lamy and Suzanne Pourbaix and has published in prestigious journals such as American Journal of Clinical Nutrition, The American Journal of Medicine and Pharmacology & Therapeutics.

In The Last Decade

C. Harvengt

96 papers receiving 940 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
C. Harvengt Belgium 18 280 257 240 193 155 100 1.0k
J.P. Desager Belgium 18 162 0.6× 189 0.7× 130 0.5× 121 0.6× 173 1.1× 68 1.1k
J. Augustín Germany 19 316 1.1× 296 1.2× 309 1.3× 165 0.9× 45 0.3× 46 1.2k
Joachim Ziegenhorn United States 13 476 1.7× 273 1.1× 358 1.5× 81 0.4× 77 0.5× 22 1.5k
Tamara A. Sutfin United States 11 243 0.9× 278 1.1× 95 0.4× 145 0.8× 142 0.9× 13 728
N. Rietbrock Germany 19 231 0.8× 78 0.3× 361 1.5× 109 0.6× 218 1.4× 147 1.4k
A.N. Chremos United States 18 97 0.3× 333 1.3× 126 0.5× 173 0.9× 108 0.7× 26 821
HF Woods United Kingdom 17 271 1.0× 141 0.5× 335 1.4× 174 0.9× 372 2.4× 28 1.2k
P W Lücker Germany 15 127 0.5× 136 0.5× 276 1.1× 188 1.0× 136 0.9× 45 969
Monique Vincent‐Viry France 18 219 0.8× 166 0.6× 327 1.4× 64 0.3× 200 1.3× 40 1.0k
E. E. Ohnhaus Switzerland 20 189 0.7× 105 0.4× 174 0.7× 113 0.6× 412 2.7× 62 1.1k

Countries citing papers authored by C. Harvengt

Since Specialization
Citations

This map shows the geographic impact of C. Harvengt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Harvengt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Harvengt more than expected).

Fields of papers citing papers by C. Harvengt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Harvengt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Harvengt. The network helps show where C. Harvengt may publish in the future.

Co-authorship network of co-authors of C. Harvengt

This figure shows the co-authorship network connecting the top 25 collaborators of C. Harvengt. A scholar is included among the top collaborators of C. Harvengt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Harvengt. C. Harvengt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Heller, F., Catherine Vandenplas, J.P. Desager, & C. Harvengt. (1993). The vitamin A fat-loading test in young normolipidemic subjects. Clinica Chimica Acta. 219(1-2). 167–176. 7 indexed citations
3.
Horsmans, Yves, J.P. Desager, R. Hulhoven, & C. Harvengt. (1993). Single‐Dose Pharmacokinetics of Cetirizine in Patients With Chronic Liver Disease. The Journal of Clinical Pharmacology. 33(10). 929–932. 24 indexed citations
4.
Horsmans, Yves, J.P. Desager, & C. Harvengt. (1992). Absence of CYP3 A Genetic Polymorphism Assessed by Urinary Excretion of 6 β‐Hydroxycortisol in 102 Healthy Subjects on Rifampicin. Pharmacology & Toxicology. 71(4). 258–261. 34 indexed citations
5.
Horsmans, Yves & C. Harvengt. (1991). Les cholestases médicamenteuses secondaires à une atteinte canalaire.. Acta gastro-enterologica belgica. 54(1). 27–33. 2 indexed citations
6.
Desager, J.P., Yves Horsmans, & C. Harvengt. (1991). Lecithin: Cholesterol Acyltransferase Activity in Familial Hypercholesterolemia Treated with Simvastatin and Simvastatin Plus Low‐Dose Colestipol. The Journal of Clinical Pharmacology. 31(6). 537–542. 11 indexed citations
7.
Horsmans, Yves, et al.. (1991). Lack of effect by nifedipine on hepatic mixed function oxidase in man. Fundamental and Clinical Pharmacology. 5(3). 193–201. 10 indexed citations
8.
Horsmans, Yves, Jean‐Pierre Desager, & C. Harvengt. (1990). Sensibilité et spécificité du dosage des catécholamines urinaires et de leurs métabolites acides dans le diagnostic du neuroblastome chez l'enfant. Bulletin du Cancer. 77(10). 985–989. 4 indexed citations
9.
Desager, Jean‐Pierre, Etienne Installé, & C. Harvengt. (1990). Plasma enoximone concentrations in cardiac patients. Current Therapeutic Research. 47(4). 743–752. 3 indexed citations
10.
Desager, J.P., et al.. (1987). Prevalence of drug hydroxylator phenotypes in Belgium. European Journal of Clinical Pharmacology. 33(4). 439–440. 8 indexed citations
11.
Desager, Jean‐Pierre, Suzanne Pourbaix, Étienne Dumont, & C. Harvengt. (1984). Metabolic Interaction of Cimetidine With Alprazolam and Triazolam After Repeated Doses. Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)). 270(1). 170–170. 1 indexed citations
12.
Harvengt, C., F. Heller, & Jean‐Pierre Desager. (1983). [Clinical-pharmacology of Lipid Lowering Drugs]. DIAL (Catholic University of Leuven). 31(4). 284–296.
13.
Harvengt, C., et al.. (1983). Effects on plasma apoproteins AI and B induced by two estro-progestin preparations: monophasic versus triphasic.. Current Therapeutic Research. 33(3). 5 indexed citations
14.
Hulhoven, R. & C. Harvengt. (1983). Disposition of Daunorubicin and Daunorubicin-dna Complex in Rabbits. Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)). 9(5). 369–373. 1 indexed citations
15.
Col, Jacques, et al.. (1982). Hemodynamic-effects of Ar-l115 Bs in Severe Chronic Congestive Heart-failure. European Journal of Clinical Investigation. 12(2). 47–47. 1 indexed citations
16.
Desager, J.P., et al.. (1982). Effect of Hemodialysis on Plasma Kinetics of Fenofibrate in Chronic Renal Failure. ˜The œNephron journals/Nephron journals. 31(1). 51–54. 22 indexed citations
17.
Harvengt, C. & Jean‐Pierre Desager. (1980). Pharmacokinetics of Fenofibrate in Man. DIAL (Catholic University of Leuven). 9(49). 3725–3727. 2 indexed citations
18.
Leonard, John P., J.P. Desager, Christian Beckers, & C. Harvengt. (1979). In vitro binding of various biological substances by two hypocholesterolaemic resins. Cholestyramine and colestipol.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 29(7). 979–81. 9 indexed citations
19.
Harvengt, C., et al.. (1978). Clinical pharmacokinetic study of procetofene, a new hypolipidemic drug, in volunteers.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 16(12). 570–4. 21 indexed citations
20.
Hulhoven, R., et al.. (1977). Daunomycin and daunomycinol plasma levels measured by HPLC after perfusions of daunomycin and daunomycin-DNA complex in rabbits: a preliminary report.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 226(2). 344–5. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J.P. Desager Breakdown of academic impact, for papers by J. Augustín Breakdown of academic impact, for papers by Joachim Ziegenhorn Breakdown of academic impact, for papers by Tamara A. Sutfin Breakdown of academic impact, for papers by N. Rietbrock Breakdown of academic impact, for papers by A.N. Chremos Breakdown of academic impact, for papers by HF Woods Breakdown of academic impact, for papers by P W Lücker Breakdown of academic impact, for papers by Monique Vincent‐Viry Breakdown of academic impact, for papers by E. E. Ohnhaus
Rankless by CCL
2026